CYTK News and Press, Cytokinetics Incorporated

2026-03-10 13:03:25 ET Roanna Ruiz from Robert W. Baird issued a price target of $84.00 for CYTK on 2026-03-10 14:28:00. The adjusted price target was set to $84.00. At the time of the announcement, CYTK was trading at $63.5453. The overall price target consensus is at $...

2026-03-09 14:38:32 ET On Feb. 5, 2026, Andrew Callos, Executive Vice President and Chief Commercial Officer of Cytokinetics (NASDAQ:CYTK) , exercised 15,000 options for common stock and immediately sold the resulting shares in an open-market transaction totaling approximately $928,...

SOUTH SAN FRANCISCO, Calif., March 02, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that members of the Company management team will participate in the following investor conferences in March: Leerink 2026 Global Healthcare Conference: Fireside chat ...

2026-02-25 01:08:32 ET More on Cytokinetics Cytokinetics, Incorporated (CYTK) Q4 2025 Earnings Call Transcript Cytokinetics, Incorporated (CYTK) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript Cytokinetics: Small Label Differences With Big Commer...

2026-02-25 01:07:53 ET Cytokinetics, Incorporated (CYTK) Q4 2025 Earnings Call February 24, 2026 4:30 PM EST... Read the full article on Seeking Alpha For further details see: Cytokinetics, Incorporated (CYTK) Q4 2025 Earnings Call Transcript

2026-02-24 18:26:24 ET Image source: The Motley Fool. Tuesday, February 24, 2026 at 4:30 p.m. ET Need a quote from a Motley Fool analyst? Email pr@fool.com Continue reading

2026-02-24 16:02:25 ET More on Cytokinetics Cytokinetics, Incorporated (CYTK) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript Cytokinetics: Small Label Differences With Big Commercial Stakes Cytokinetics, Incorporated (CYTK) Discusses FDA Approva...

MYQORZO® Approved for Adults with Symptomatic Obstructive HCM in U.S., China and Europe;  U.S. Launch Underway with First Prescriptions Dispensed within Days of Drug Availability Supplemental NDA for MAPLE-HCM Submitted to FDA in Q1 2026 Expect to Share Topline Results from AC...

Interface Inc. (TILE) is expected to report $0.4 for Q4 2025 Evolent Health Inc Class A (EVH) is expected to report $-0.03 for Q4 2025 MercadoLibre Inc. (MELI) is expected to report $11.77 for Q4 2025 Clean Energy Fuels Corp. (CLNE) is expected to report $-0.1 for Q4 2025 Kiniksa ...

2026-02-19 11:28:56 ET Bristol-Myers Squibb Company ( BMY ) shares have risen 27.7% since my last article , " Why Bristol-Myers Squibb Remains Undervalued In 2025," in mid-November. They have outperformed the S&P 500 [3.6% return] ( SPY ) during that time.... R...